Ledger. Australian venture funding, tracked

Company

Radiopharm Theranostics

Company where Dr Baker was a non-executive director between 2021 and 2024

Coverage

Stories naming Radiopharm Theranostics. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Key hire

Percheron turns to former Arovella chief Michael Baker for next phase of HMBD-002 development

Percheron Therapeutics has appointed Arovella Therapeutics' former leader Michael Baker as CEO from October, with James Garner departing for an overseas role while joining the board as a non-executive director.

35 deals

FUNDED October 2022

Techboard's monthly roundup tallies October 2022 startup funding at $661m across 99 deals, listing megadeals such as Airwallex, acquisitions, Square Peg's $861m fund close and government grants to program operators.

Also @AuManufacturing

Unnamed stage $2m

Healthcare & Fitness

AFR healthcare and fitness section roundup: Early Bird raised $2 million led by Hyper Ventures; Resmed sold MatrixCare; Radiopharm seeks $16 million; plus Mayne Pharma, Healthscope, Sigma and policy stories.

Also SmartCompany

Something wrong? Tell us